PL2869836T3 - Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki - Google Patents

Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki

Info

Publication number
PL2869836T3
PL2869836T3 PL13732833T PL13732833T PL2869836T3 PL 2869836 T3 PL2869836 T3 PL 2869836T3 PL 13732833 T PL13732833 T PL 13732833T PL 13732833 T PL13732833 T PL 13732833T PL 2869836 T3 PL2869836 T3 PL 2869836T3
Authority
PL
Poland
Prior art keywords
pancreatic cancer
cancer patients
dna vaccine
vaccine
dna
Prior art date
Application number
PL13732833T
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of PL2869836T3 publication Critical patent/PL2869836T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/852Pancreas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13732833T 2012-07-05 2013-06-26 Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki PL2869836T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12004995 2012-07-05
EP13732833.2A EP2869836B1 (en) 2012-07-05 2013-06-26 Dna vaccine for use in pancreatic cancer patients
PCT/EP2013/001882 WO2014005683A1 (en) 2012-07-05 2013-06-26 Dna vaccine for use in pancreatic cancer patients

Publications (1)

Publication Number Publication Date
PL2869836T3 true PL2869836T3 (pl) 2020-03-31

Family

ID=48741047

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13732833T PL2869836T3 (pl) 2012-07-05 2013-06-26 Szczepionka DNA do zastosowania u pacjentów z rakiem trzustki

Country Status (19)

Country Link
US (3) US9415098B2 (pl)
EP (2) EP3603664A1 (pl)
JP (1) JP6325534B2 (pl)
KR (1) KR102090612B1 (pl)
CN (1) CN104519908B (pl)
AU (2) AU2013286335B2 (pl)
BR (1) BR112014033046A2 (pl)
DK (1) DK2869836T3 (pl)
ES (1) ES2752141T3 (pl)
HU (1) HUE046138T2 (pl)
IL (1) IL236049B (pl)
LT (1) LT2869836T (pl)
MX (1) MX359315B (pl)
PL (1) PL2869836T3 (pl)
RU (1) RU2636348C2 (pl)
SG (1) SG11201500054QA (pl)
SI (1) SI2869836T1 (pl)
WO (1) WO2014005683A1 (pl)
ZA (1) ZA201409156B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005683A1 (en) 2012-07-05 2014-01-09 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
ES2760699T3 (es) * 2015-06-18 2020-05-14 Vaximm Ag Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
CA3028549A1 (en) * 2016-07-13 2018-01-18 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy
WO2018066277A1 (ja) 2016-10-07 2018-04-12 デンカ株式会社 窒化ホウ素塊状粒子、その製造方法及びそれを用いた熱伝導樹脂組成物
WO2018074077A1 (ja) 2016-10-21 2018-04-26 デンカ株式会社 球状窒化ホウ素微粉末、その製造方法及びそれを用いた熱伝導樹脂組成物
MX2019005212A (es) * 2016-11-04 2019-06-20 Vaximm Ag Vacuna de adn dirigida a wt1 para terapia de combinacion.
JP7712060B2 (ja) 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規vegfr-2ターゲット免疫療法アプローチ
CA3056807A1 (en) 2017-03-17 2018-09-20 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
KR20210058825A (ko) * 2018-09-05 2021-05-24 백심 아게 병용 요법용 신생항원 표적화 dna 백신
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR20220128638A (ko) 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
WO2023105076A1 (en) * 2021-12-09 2023-06-15 Prokarium Limited Combination cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001382B1 (ko) 1990-09-05 1993-02-27 보령신약 주식회사 경구용 장티프스 생균백신 및 그의 제조방법
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
JP6251179B2 (ja) * 2011-12-22 2017-12-20 バクシム アクチェンゲゼルシャフト 弱毒化サルモネラ株を高収量で生産する方法
WO2014005683A1 (en) * 2012-07-05 2014-01-09 Vaximm Ag Dna vaccine for use in pancreatic cancer patients

Also Published As

Publication number Publication date
AU2013286335A1 (en) 2015-01-29
US9415098B2 (en) 2016-08-16
WO2014005683A1 (en) 2014-01-09
CN104519908B (zh) 2020-10-30
ES2752141T3 (es) 2020-04-03
HUE046138T2 (hu) 2020-02-28
MX2014015977A (es) 2015-03-20
WO2014005683A8 (en) 2014-04-03
SI2869836T1 (sl) 2020-01-31
JP2015522263A (ja) 2015-08-06
CN104519908A (zh) 2015-04-15
US10293037B2 (en) 2019-05-21
KR20150036361A (ko) 2015-04-07
US20190008936A1 (en) 2019-01-10
JP6325534B2 (ja) 2018-05-16
EP3603664A1 (en) 2020-02-05
LT2869836T (lt) 2019-11-11
SG11201500054QA (en) 2015-03-30
AU2013286335B2 (en) 2017-08-10
US20160250311A1 (en) 2016-09-01
EP2869836A1 (en) 2015-05-13
KR102090612B1 (ko) 2020-03-19
CA2877938A1 (en) 2014-01-09
ZA201409156B (en) 2016-07-27
DK2869836T3 (da) 2019-11-25
AU2017258877A1 (en) 2017-11-30
IL236049B (en) 2020-04-30
US20150165011A1 (en) 2015-06-18
RU2636348C2 (ru) 2017-11-22
BR112014033046A2 (pt) 2017-06-27
IL236049A0 (en) 2015-01-29
AU2017258877B2 (en) 2018-11-29
MX359315B (es) 2018-09-25
RU2015103758A (ru) 2016-08-27
EP2869836B1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
ZA201409156B (en) Dna vaccine for use in pancreatic cancer patients
IL238249B (en) Cancer treatment
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2815361A4 (en) DISPOSABLE PAYMENT CARDS
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
EP2892490A4 (en) PATIENT SUPPORT
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
SG11201500396TA (en) Tumor vaccination
HUE039650T2 (hu) Rendszer gyógykezeléshez
PL2914721T3 (pl) Cząsteczka trans-splicingująca RNA (RTM) do zastosowania w leczeniu raka
GB201218084D0 (en) Novel compounds and methods for use in medicine
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
ZA201402071B (en) Vaccine therapy
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
DK2872176T3 (en) Cancer treatment
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201215502D0 (en) Medical use
IL239231A0 (en) Combined cancer treatment
GB201107549D0 (en) Cancer vaccine
GB201201728D0 (en) Improvements in or relating to patient support
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer
AU2012900259A0 (en) Agents for use in cancer therapy
GB201213192D0 (en) Support for therapeutic
AU2012905667A0 (en) Vaccines for treatment of cancer